Vertebroplasty versus conservative treatment for vertebral fractures
Date of this Version
Although Caroline Klazen and colleagues acknowledge that the main drawback of their open-label trial of vertebroplasty (Vertos II; Sept 25, p 1085)¹ was the lack of blinding, they do not mention that this is likely to overestimate the true benefit of vertebroplasty. Lack of blinding results in an average over estimate of relative treatment benefit of about 25%², which could explain these results.
This document has been peer reviewed.